RxDoctor Payments Data

Martin Korkowski, MD

Internal Medicine · Leesburg, VANPI 1801880752

Payments from drug & device makers

$1,771in general payments, 2019–2025

Across 97 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$445
  • Pfizer$206
  • AbbVie$182
  • Boehringer Ingelheim$161
  • AstraZeneca$119
  • Kowa Pharmaceuticals America, Inc.$98
  • plus $560 from 12 others

What the payments were for

  • Food & beverage$1,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,771 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$104,776
Medicare patients
304
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$49,452
EliquisApixaban33$33,029
JanuviaSitagliptin Phosphate23$28,924
TradjentaLinagliptin31$22,367
JanumetSitagliptin Phos/Metformin Hcl11$16,161
LinzessLinaclotide19$15,663
Breo ElliptaFluticasone/Vilanterol25$12,363
TrulicityDulaglutide11$10,500
LivaloPitavastatin Calcium13$9,131
FarxigaDapagliflozin Propanediol12$8,017
Synjardy XrEmpagliflozin/Metformin Hcl11$6,564
MyrbetriqMirabegron11$5,392
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,045
Insulin Lispro Kwikpen U-100Insulin Lispro13$2,826
Estradiol35$2,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$161$78,383100 claims
PfizerEliquis, Paxlovid$206$34,39650 claims
AbbVieLinzess, Synthroid, Armour Thyroid$182$19,52481 claims
GSKBreo Ellipta$33$12,36325 claims
Lilly USA, LLCTrulicity$44$10,50011 claims
Kowa Pharmaceuticals America, Inc.Livalo$98$9,13113 claims
AstraZenecaFarxiga$119$8,01712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →